Introduction
============

Cancer has become a global public health problem, seriously endangering human life in recent decades.[@b1-ott-11-3541] Early diagnosis of cancer greatly improves the survival of patients and their quality of life; however, there is no effective way to assess the prognosis of cancer patients based on clinical parameters. microRNAs (miRNAs), as a new type of biomarker, have gradually attracted the attention of many researchers.[@b2-ott-11-3541] miRNAs are non-coding RNAs of approximately 18--25 nucleotides that facilitate messenger RNA (mRNA) degradation and inhibit translation by binding to the 3′-untranslated region of the mRNA.[@b3-ott-11-3541]

Recently, a growing amount of evidence has shown that miRNAs are engaged in diverse biological processes, including cellular growth, differentiation, proliferation, metastasis, invasion, migration, and apoptosis.[@b4-ott-11-3541]--[@b8-ott-11-3541]

The miR-17-92 cluster (which is situated at the human 13q31 and includes miR-17-3p, miR-17-5p, miR-19a, miR-18a, miR-19b, miR-20a, and miR-92-1) first attracted the attention of researchers after a series of reports linked these miRNAs to tumor formation and progression.[@b9-ott-11-3541] Specifically, researchers have found that miR-17-5p is a crucial member of the miR-17 cluster family that is highly expressed in various cancers such as hepatocellular carcinoma (HCC),[@b10-ott-11-3541],[@b11-ott-11-3541] lung cancer (LC),[@b12-ott-11-3541] colorectal cancer (CRC), [@b13-ott-11-3541] and other cancers.[@b13-ott-11-3541]--[@b18-ott-11-3541]

Furthermore, researchers have found that high expression of miR-17-5p is negatively correlated with overall survival (OS) and disease-free survival (DFS) in different kinds of cancers.[@b10-ott-11-3541],[@b11-ott-11-3541],[@b19-ott-11-3541] However, some studies have reported contradictory results; for example, Liu et al[@b20-ott-11-3541] observed that high expression of miR-17-5p could negatively regulate the invasion and migration of HCC cell lines. Until now, a systematic review of the prognostic value of miR-17-5p in human tumors has not been reported. Therefore, we performed this meta-analysis to explore the prognostic role of elevated miR-17-5p expression in various cancers.

Materials and methods
=====================

Literature search
-----------------

To identify relevant studies, we searched the online PubMed, EMBASE, Web of Science, and the Cochrane library database through July 2017. The keywords for the search were as follows: "miR-17-5p", "microRNA-17-5p", "miRNA-17-5p", "cancer", "carcinoma", "neoplasm", and "tumor" in combination with "prognosis". In addition, the references of identified articles were also explored for additional relevant articles. All of the articles were reviewed by three investigators independently, and any disagreements were settled by discussion.

Inclusion and exclusion criteria
--------------------------------

Researchers first screened the title and abstract and then screened out articles by skimming the full text. An eligible study was selected if it was consistent with the following inclusion criteria: 1) the study was based on human research; 2) hazard ratios (HRs) and their 95% confidence intervals (CIs) could be extracted from the article; 3) all patients could be separated into high and low expression level groups based on miR-17-5p quantity; and 4) the study was written in English and its full text was available.

Exclusion criteria for the articles were as follows: 1) the study was conducted using animals and/or cell lines; 2) the study was a systematic review or case report; 3) the study was not written in English; 4) the study lacked significant data; and 5) the study was a repeat study.

Data extraction
---------------

Three investigators (Kong WH, Cheng YS, and Liang H) extracted the data and information from the selected studies. Any disagreements were resolved through a panel discussion. Extracted data from the eligible studies included cancer type, the first author's surname, country, sample size, specimen source, test method, criteria for high miR-17-5p expression, rate of high miR-17-5p expression, follow-up period, age, gender, tumor depth, lymph node invasion, metastasis, vein invasion, histology differentiation, tumor size, and HRs with corresponding 95% CIs for OS, progress-free survival (PFS), and DFS.

Quality evaluation
------------------

We assessed the selected studies using the MOOSE method proposed by the Netherland Cochrane Center. The basic principles of this analysis included determining if 1) the number of patients was sufficient; 2) the design method was clear; 3) sufficient data were reported; 4) the results were clearly evaluated; 5) miR-17-5p measurement was described in detail; and 6) adequate follow-up time was available for each study.[@b21-ott-11-3541] Studies that did not meet the above six requirements were excluded.

Statistical analysis
--------------------

Statistical analyses of the HRs for OS, DFS, and odds ratios (ORs) for clinicopathological characteristics were computed using STATA and RevMan software. Heterogeneity was assessed using *Q* tests and *I*[@b2-ott-11-3541] statistics (*P*\<0.05 or *I*[@b2-ott-11-3541]\>50% was deemed to be statistically heterogeneous). When the heterogeneity of the combined study was small (*I*[@b2-ott-11-3541]\<50%, *P*\<0.10), we used the fixed effect model for statistical analysis. Otherwise, a random effects model was used. Subgroup analysis was conducted to further explore the association of miR-17-5p with sample size, ethnicity, source, definition method, tumor type, and statistical mode for various carcinomas. We used Egger's test, Begg's test, and funnel plots to detect publication bias. Sensitive analysis was also implemented to evaluate the stabilization of the results. A *P*-value below 0.05 was deemed to be statistically significant.

Results
=======

Literature search and study characteristics
-------------------------------------------

According to the inclusion and exclusion criteria, we selected a total of ten articles with data from approximately 1,135 people for meta-analysis, and the detailed selection steps are shown in [Figure 1](#f1-ott-11-3541){ref-type="fig"}.

We summarize the major features of the selected studies in [Table 1](#t1-ott-11-3541){ref-type="table"}. Among these ten studies, nine measured miR-17-5p expression using polymerase chain reaction (PCR), while one study performed PCR and in situ hybridization (ISH). Across these the ten studies, patients were diagnosed with CRC HCC, colon cancer (CC), gastric cancer (GC), childhood infratentorial ependymoma (CIE), pancreatic cancer (PC), osteosarcoma (OSA), nasopharyngeal carcinoma (NPC), and LC. Eight studies directly provided HRs and 95% CIs, one study provided only a survival curve, and one study provided only the risk ratios (RRs); thus, we merged RRs and HRs.

miR-17-5p expression and OS
---------------------------

We included ten studies of OS in our analysis. Considering that potential heterogeneity may have been introduced in this study, we used a random effect model to conservatively estimate the effect of combined HRs and 95% CIs. We found that patients with high expression of miR-17-5p had a worse prognosis than those with low expression of miR-17-5p (HR=1.87; 95% CI, 1.37--2.55; *P*=0.000) ([Figure 2](#f2-ott-11-3541){ref-type="fig"}).

To lessen the impact of heterogeneity, subgroup analyses were performed for sample size, ethnicity, sources of detected sample source, definition method, tumor types, and statistical mode ([Table 2](#t2-ott-11-3541){ref-type="table"}). First, we found that the expression level of miR-17-5p had a statistically significant effect on OS in subgroups with a sample size greater than or equal to 100 (HR=2.15; 95% CI, 1.37--3.37; *P*=0.001) as well as subgroups with a sample size of less than 100 (HR=1.72; 95% CI, 1.11--2.68; *P*=0.016). Second, we observed that miR-17-5p had a statistically significant effect on OS in the Asians patient subgroup (HR=1.92; 95% CI, 1.37--2.71; *P*=0.000), but no statistical significance was found in the European patient subgroup. Third, when we conducted a subgroup analysis for the sample source, we found that miR-17-5p was more strongly associated with the plasma/serum subgroup (HR=2.13; 95% CI, 1.36--3.31; *P*=0.001) than the tissue subgroup (HR=1.69; 95% CI, 1.05--2.71; *P*=0.031) using a random effects model. Fourth, miR-17-5p has a stronger correlation with median definition than other definition methods (HR=2.08; 95% CI, 1.54--2.81; *P*=0.000). Fifth, in a subgroup analysis stratified by the cancer type, all three of the subgroups showed a strong correlation between miR-17-5p and OS with a random effects model, indicating that miR-17-5p has a predictive effect for different kinds of tumors. Finally, considering that the combination of univariate analysis and multivariate analysis is unreasonable, we performed a subgroup analysis for statistical mode, and the results were consistent with the overall combined effect. Therefore, the conclusion is stable and credible.

miR-17-5p expression and DFS
----------------------------

Two studies focused on DFS analysis. Heterogeneity results showed a small amount of heterogeneity (*I*^2^=0; *P*=0.360), so we use a fixed effect model to compute the combined HRs and 95% CIs for DFS. The results showed that the DFS of patients with elevated miR-17-5p expression was more affected than that of patients with decreased miR-17-5p expression (HR=1.60; 95% CI, 1.05--2.44; *P*=0.027) ([Figure 3](#f3-ott-11-3541){ref-type="fig"}). Because only two studies reported DFS, the data are too limited to perform subgroup analysis for DFS.

miR-17-5p expression and clinicopathological characteristics
------------------------------------------------------------

Meta-analysis indicated that elevated miR-17-5p expression was associated with lymph node invasion (OR=1.28; 95% CI, 1.05--1.56; *P*=0.016) and venous invasion (OR=1.92; 95% CI, 1.40--2.63; *P*=0.000) ([Table 3](#t3-ott-11-3541){ref-type="table"}). No significant correlations were found for age (*P*=0.24), gender (*P*=0.212), tumor invasion depth (*P*=0.400), distant metastasis (*P*=0.499), tumor stage (*P*=0.804), differentiation grade (*P*=0.077), tumor size (*P*=0.291), or hepatitis history (*P*=0.550). Due to insufficient data, we failed to detect any correlations between elevated miR-17-5p expression and other clinicopathological characteristics.

Sensitivity analysis
--------------------

Sensitivity analysis was implemented to assess the influence of each individual study on the integrated results of OS. We excluded each study, re-merged the meta-analysis results and then compared the results of the unexcluded meta-analysis to investigate the stability of the results. This analysis showed that the combined HR for the effect of miR-17-5p expression on OS was not remarkably influenced after eliminating any of the individual studies ([Figure 4](#f4-ott-11-3541){ref-type="fig"}).

Publication bias
----------------

We use Egger's tests and funnel plots to detect the publication bias. The results of the funnel plot for OS are shown in [Figure 5](#f5-ott-11-3541){ref-type="fig"}. Since the Egger's test has a *P*-value greater than 0.05, no publication bias was found. Due to the small number of studies that reported DFS, we were not able to determine the publication bias for DFS.

Discussion
==========

In recent years, miRNAs have been considered to be closely related to carcinogenic processes such as angiogenesis, proliferation, differentiation, invasion, apoptosis, and metastasis.[@b9-ott-11-3541] It is presumed that more than one third of human genes are regulated by miRNAs,[@b22-ott-11-3541] which serve as negative regulatory molecules of gene expression at the posttranscriptional translation phase and are widely involved in the development and progression of human diseases, particularly human cancer.[@b23-ott-11-3541] Since the publication of reviews about miRNA-17-5p in multiple journals, miR-17-5p has gradually attracted the attention of many researchers as a molecule of interest. miR-17-5p has also been found to be closely associated with the development of tumors.[@b9-ott-11-3541],[@b24-ott-11-3541]--[@b26-ott-11-3541] However, as no quantitative systematic reviews about miR-17-5p have been published so far, we conducted this meta-analysis.

In this study, we strictly adhered to the MOOSE guidelines to perform the meta-analysis and to assess the quality of the included studies using the scales recommended by the Cochrane Collaboration.[@b21-ott-11-3541] The results indicated that high expression of miR-17-5p plays an unfavorable role in OS and DFS. Considering the potential heterogeneity of the included studies, we used a random effects model to combine the data and then performed subgroup analysis, sensitivity analysis, and publication bias detection; the findings of these analyses show that our results are stable and credible.

Furthermore, we carried out subgroup analyses to explore the prognostic significance of miR-17-5p in OS, and we have successfully drawn some valuable conclusions for clinical practice. To rule out the impact of different races on prognosis, we divided the ten studies into patient groups of Asian and European ethnicities. We observed that the elevated expression of miR-17-5p predicts significantly worse OS in Asian patients (pooled HR=1.92; 95% CI, 1.37--2.71; *P*=0.000), but no statistical significance was found in European patients (combined HR=1.69; 95% CI, 0.57--5.00, *P*=0.344) ([Table 2](#t2-ott-11-3541){ref-type="table"}). This difference may be due to the different genetic backgrounds, geographical locations, climates etc., of the different races. Therefore, we concluded that miR-17-5p might be a more valuable predictor of cancer prognosis in Asian populations. To illustrate the relationship between the expression level of miR-17-5p and prognosis using different sample sources, we divided the patients into two subgroups, serum/plasma and tissue, and we observed that the serum/plasma group had a worse prognosis (combined HR=2.13; 95% CI, 1.36--3.31; *P*=0.001) than tissue-derived specimens (combined HR=1.69; 95% CI, 1.05--2.71; *P*=0.031) ([Table 2](#t2-ott-11-3541){ref-type="table"}). Although the detection of miR-17-5p in tumor specimens has been widely used to study tumor prognosis, plasma/serum specimen detection is more convenient and effective, and it can efficiently assess the risk of hospital stay and postoperative recurrence. The expression of miR-17-5p in the blood is more predictive than in tissue, which can be applied in clinical research. Therefore, the detection of miR-17-5p in plasma/serum during postoperative follow-up periods might be an effective way to closely monitor disease-progression and treatment in cancer patients.

Moreover, we carried out meta-analyses with respect to pathological characteristics. We found that elevated miR-17-5p expression is predominantly correlated with lymph node invasion (combined OR=1.28; 95% CI, 1.05--1.56; *P*=0.016) and venous invasion (combined OR=1.92; 95% CI, 1.40--2.63; *P*=0.000). No statistically significant correlations were found for age, gender, tumor invasion depth, distant metastasis, tumor stage, differentiation grade, or hepatitis history. Therefore, we concluded that miR-17-5p may be involved in the progression of lymphatic metastasis and vein invasion in cancer.

To the best of our knowledge, miR-17-5p has been found to be closely associated with cancers through complicated regulatory mechanisms.[@b9-ott-11-3541] For instance, Yang et al[@b27-ott-11-3541] observed that miR-17-5p can facilitate the migration and proliferation of human liver cancer cells through the p38-MAPK-HSP27 pathway. Li et al[@b28-ott-11-3541] discovered that miR-17-5p can boost the invasion and migration of human breast tumor cells by inhibiting HMG box-containing protein 1 (HBP1), a tumor suppressor. Qu et al[@b29-ott-11-3541] observed that miR-17-5p can negatively regulate transforming growth factor-beta receptor 2 (TGFBR2), which serves as an original regulator of the TGF-beta signaling pathway, and reduction or loss of its expression can lead to uncontrolled cell proliferation and invasion, thus promoting cell growth and migration. Wang et al[@b30-ott-11-3541] noticed that miR-17-5p can promote the proliferation of OSA in a breast cancer cell 2 (BRCC2)-dependent mechanism, which plays a key role in suppressing tumorigenesis. To some extent, these mechanisms explain why patients with elevated miR-17-5p expression have multiple lymphatic metastases and venous violations, but the specific mechanism still requires further investigation.

These studies had several limitations. First, the definition of high miR-17-5p expression was not the same across studies; thus, it was difficult to define miR-17-5p overexpression in various cancers. Second, the study included a total of only ten articles; therefore, the data are not sufficient. Third, there was considerable heterogeneity among the different studies in terms of cancer type, specimen source, detection method and definition of high miR-17-5p expression. Fourth, eligible studies only included positive results, and there may be publication bias. Fifth, combining univariate and multivariate analysis is somewhat unreasonable. Finally, part of the HR value was calculated using a survival curve, which may lead to some error.

Conclusion and recommendations
==============================

Our meta-analysis has explored the predictive value of miR-17-5p in different types of carcinomas. miR-17-5p may serve as a new tumor marker for predicting prognosis and for evaluating the clinicopathological characteristics of different kinds of carcinomas. Ultimately, considering the limitations of this study, these conclusions require additional large-sample and high-quality research to further clarify the relationship between miRNA-17-5p and prognosis.
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![Begg's funnel plot with pseudo 95% CI of the publication bias for overall survival.\
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###### 

Characteristics of the included studies

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tumor type   Reference                            Region   Sample size   Specimen source   Test method   Definition of high miR-17-5p expression   Rate of high miR-17-5p expression   Tumor stage                        Follow-up time (months)                  Survival   HR
  ------------ ------------------------------------ -------- ------------- ----------------- ------------- ----------------------------------------- ----------------------------------- ---------------------------------- ---------------------------------------- ---------- ----
  HCC          Chen et al[@b10-ott-11-3541]         China    120           Tissue            PCR           Median                                    56.7                                Edmondson--Steiner grade (I--IV)   2--46                                    OS^MA^\    RR
                                                                                                                                                                                                                                                                     DFS^MA^    

  CIE          Zakrzewska et al[@b15-ott-11-3541]   Poland   53            Tissue            PCR           Median                                    NR                                  WHO (I--III)                       Up to 120                                OS^MA^\    R
                                                                                                                                                                                                                                                                     EFS^MA^    

  GC           Wang et al[@b17-ott-11-3541]         China    65            Plasma            PCR           Median                                    50.8                                TNM (I--IV)                        Up to 40                                 OS^UA^     R

  CC           Diaz et al[@b18-ott-11-3541]         Spain    62            Tissue            PCR           Tertile                                   33.9                                TNM (I--IV)                        68--99                                   OS^UA^\    R
                                                                                                                                                                                                                                                                     DFS^UA^    

  HCC          Zheng et al[@b11-ott-11-3541]        China    96            Serum             PCR           Median (2.705)                            50                                  TNM (I--IV)                        From resection to death or May 1, 2012   OS^MA^     R

  PC           Yu et al[@b19-ott-11-3541]           Japan    80            Tissue            PCR           Cutoff value (5.69)                       37.5                                UICC (I--IV)                       Up to 100                                OS^MA^     R

  CRC          Fang et al[@b13-ott-11-3541]         China    295           Tissue            PCR ISH       Staining score (8--12)                    30.2                                TNM (I--IV)                        Up to 96                                 OS^MA^     R

  NPC          Chen et al[@b16-ott-11-3541]         China    81            Tissue            PCR           Staining score (tai)                      75.3                                TNM (I--IV)                        Up to 100                                OS^UA^     SC

  LC           Chen et al[@b12-ott-11-3541]         China    221           Serum             PCR           Median (33 months)                        45.7                                TNM (I--IV)                        Up to 50                                 OS^UA^     R

  OSA          Zhu et al[@b14-ott-11-3541]          China    62            Plasma            PCR           Mean                                      NR                                  TNM (I--III)                       10--70 (OS)\                             OS^MA^\    R\
                                                                                                                                                                                                                            10--60 (PFS)                             PFS^MA^    
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** HR, hazard ratio; HCC, hepatocellular carcinoma; CIE, childhood infratentorial ependymoma; GC, gastric cancer; CC, colon cancer; PC, pancreatic cancer; CRC, colorectal cancer; NPC, nasopharyngeal carcinoma; LC, lung cancer; OSA, osteosarcoma; PCR, polymerase chain reaction; ISH, in situ hybridization; NR, not reported; WHO, World Health Organization; TNM, tumour node metastases; UICC, Union for International Cancer Control; OS, overall survival; PFS, progress-free survival; DFS, disease-free survival; MA, multivariate analysis; UA, univariate analysis; RR, risk ratio; R, reported; SC, survival curve.

###### 

The pooled HRs, 95% CIs, heterogeneity, and *P*-values of overall survival stratified by sample size, ethnicity, sample sources, definition method, tumor type, and statistical mode

  Stratified analysis      Number of studies   Number of patients   Pooled HR (95% CI)       *P*-value   Heterogeneity   Test of interaction            
  ------------------------ ------------------- -------------------- ------------------------ ----------- --------------- --------------------- -------- ------
  Sample size                                                                                                                                           0.49
   ≥100                    3                   636                  **2.15 (1.37--3.37)**    0.001       38.6            0.196                 Random   
   \<100                   7                   499                  **1.72 (1.11--2.68)**    0.016       48.6            0.070                 Random   
  Dominant ethnicity                                                                                                                                    0.82
   Asian                   8                   1,020                **1.92 (1.37--2.71)**    0.000       47.2            0.066                 Random   
   European                2                   115                  1.69 (0.57--5.00)        0.344       55.6            0.133                 Random   
  Source                                                                                                                                                0.48
   Tissue                  6                   691                  **1.69 (1.05--2.71)**    0.031       50.7            0.071                 Random   
   Serum/plasma            4                   444                  **2.13 (1.36--3.31)**    0.001       40.5            0.169                 Random   
  Definition                                                                                                                                            0.80
   Median                  5                   555                  **2.08 (1.54--2.81)**    0.000       1.5             0.398                 Random   
   Stain score             2                   376                  1.77 (0.57--5.50)        0.327       76.4            0.015                 Random   
   Others                  3                   204                  **1.76 (1.15--2.67)**    0.008       0               0.438                 Random   
  Tumor types                                                                                                                                           0.15
   Digestive system        6                   718                  **1.73 (1.20--2.49)**    0.003       45.2            0.104                 Random   
   Respiratory system      2                   302                  **1.63 (1.02--2.60)**    0.040       0               0.531                 Random   
   Others                  2                   115                  **5.33 (1.72--16.50)**   0.004       27.3            0.241                 Random   
  Statistical mode                                                                                                                                      0.19
   Univariate analysis     4                   429                  **1.59 (1.17--2.17)**    0.003       0               0.663                 Random   
   Multivariate analysis   6                   706                  **2.43 (1.39--4.26)**    0.002       61.4            0.024                 Random   

**Note:** Data in bold *P*\<0.05.

**Abbreviations:** CI, confidence interval; HR, hazard ratio.

###### 

Meta-analysis results of the correlation between elevated miR-17-5p expression and multiple clinicopathological characteristics

  Stratified analysis                                     Number of studies   Number of patients   Pooled OR (95% CI)      *P*-value   Heterogeneity           
  ------------------------------------------------------- ------------------- -------------------- ----------------------- ----------- --------------- ------- --------
  Age (old vs young)                                      6                   663                  1.08 (0.95--1.24)       0.240       0               0.578   Fixed
  Gender (male vs female)                                 6                   663                  0.92 (0.80--1.05)       0.212       0               0.809   Fixed
  Invasion depth (T3+T4 vs T1+T2)^\*^                     2                   160                  1.45 (0.61--3.45)       0.400       87.7            0.004   Random
  Lymph node invasion (≥2 vs \<2)                         2                   201                  **1.28 (1.05--1.56)**   0.016       0               0.404   Fixed
  Distant metastasis (yes vs no)                          3                   242                  1.24 (0.66--2.32)       0.499       83.4            0.002   Random
  Tumor stage (III+IV vs I+II)                            4                   463                  1.09 (0.56--2.10)       0.804       88.8            0.000   Random
  Venous invasion (yes vs no)                             2                   200                  **1.92 (1.40--2.63)**   0.000       0               0.776   Fixed
  Differentiation grade (poorly vs well and moderately)   2                   161                  1.33 (0.97--1.84)       0.077       0               0.361   Fixed
  Tumor size (\>5 vs \<5) (cm)                            3                   281                  0.90 (0.62--1.30)       0.291       53.4            0.117   Random
  Hepatitis history (yes vs no)                           3                   216                  1.20 (0.66--2.16)       0.550       58.9            0.119   Random

**Notes:** According to the size of the tumor and/or the extent of the primary tumor are defined as different T stages. Data in bold *P*\<0.05.

**Abbreviations:** CI, confidence interval; OR, odds ratio.
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